Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
The Acquired Metabolic Disorders of the Nervous System, High-Altitude (mountain) sickness
Adams & Victors Principles of Neurology Chp 40, pg 1139, Ropper, A.H.,et al, 2014
Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012
Preexposure Prophylaxis for HIV - Where Do We Go from Here?
NEJM 367:459-461,462, Cohen, M.S. & Baden, L.R., 2012
Hyperosmolar Therapy for Raised Intracranial Pressure
NEJM 367:746-752, Ropper, A.H., 2012
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Tension-Type Headache
JAMA 306:450, Pluta, R.M.,et al, 2011
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
NEJM 365:493-505,561, Cohen, M.S.,et al, 2011
Analysis of Relapses in Anti-NMDAR Encephalitis
Neurol 77:996-999, Gabilondo, I.,et al, 2011
HIV Screening of Male Inmates During Prison Intake Medical Evaluation - Washington, 2006-2010
JAMA 306:1756-1757, Strick, L.B., 2011
Impact of Late Diagnosis and Treatment on Life Expectancy in People with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
BMJ 343:d6016,d6015, May, M.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
Antiretroviral Prophylaxis: A Defining Moment in HIV Control
Lancet 378:e23-25, Karim, S.S. and Karim, Q.A., 2011
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Changes in the Incidence and Predictors of Human Immunodeficiency Virus-Associated Dementia in the Era of Highly Active Antiretroviral Therapy
Ann Neurol 63:213-221, Bhaskaran,K.,et al, 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007
Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Parkinson Disease
Neurol 66:1097-1099, Hernan,M.A.,et al, 2006
Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs
Stroke 34:379-386, Bak,S.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
HIV-associated Neurologic Disease Incidence Changes: Multicenter AIDS Cohort Study, 1990-1998
Neurol 56:257-260, Sacktor,N.,et al, 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Decreasing Incidence of CNS AIDS-Defining Events Associated with Antiretroviral Therapy
Neurol 54:1856-1859, d'Arminion Monforte,A.,et al, 2000
Incidence and Prevalence of Neurological Disorders Associated with HIV Since the Introduction of Highly Active Antiretroviral Therapy (HAART)
JNNP 69:376-380, Maschke,M. et al, 2000
Anti-Inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Arch Neurol 57:1586-1591, Broe,G.A.,et al, 2000
AIDS-Related Focal Brain Lesions in the Era of Highly Active Antiretroviral Therapy
Neurol 55:1194-1200, Ammassari,A.,et al, 2000
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Do Antiarthritic Drugs Decrease Risk for Cognitive Decline? Data From Trtm Trial of Hypertension in Older Adults
Neurol 50:374-379, Prince,M.,et al, 1998
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
NEJM 336:973-979, 1014-10161997., Ridker,P.M.,et al, 1997
1997 USPHS/IDSA Guidelines for Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus
Ann Int Med 127:923-946, , 1997
USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV:A Summary
Ann Int Med 124:349-361, 3421996., , 1996
Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996
Nerve Growth Factor and Diabetic Neuropathy
Lancet 348:1044-1045, Dyck,P.J., 1996
Primary Prevention of Cryptococcal Meningitis by Fluconazole in HIV Infected Patients
Lancet 345:548-552, 5301995., Quagliarello,V.J.,et al, 1995